EU Panel Backs Merck RSV Shield for Young Children
A European Medicines Agency committee recommended expanded use of Merck's Enflonsia to prevent respiratory syncytial virus in certain children up to 24 months.
Updated on Nov. 13, 2026 in Children’s Health

Live Poll
Do you trust new preventive medicines for young children once regulators approve them?
The Committee for Medicinal Products for Human Use adopted a positive opinion recommending Merck's Enflonsia for preventing RSV in certain children up to 24 months old. Merck announced the opinion on Friday.
Why it matters
Some children remain at increased risk of serious RSV-related bronchiolitis or pneumonia after their first RSV season, so a preventive option for a wider age range addresses an ongoing gap. The recommendation moves the treatment closer to availability across the European Union, Iceland, Liechtenstein and Norway.
The recommendation is a positive committee opinion covering children up to 24 months, with the age ceiling set at the second RSV season. The European Commission's final decision on marketing authorization has not yet been made.
The players
Merck
Merck is a global pharmaceutical company headquartered in Rahway, New Jersey, that develops prescription medicines and vaccines.
The details
The committee recommended Enflonsia for children at increased risk for severe disease through their second RSV season, a group that remains vulnerable after their first season. The European Commission will now review the recommendation before any marketing authorization is granted in the European Union, Iceland, Liechtenstein and Norway.
Timeline
Friday: Merck announced the positive committee opinion.
Within the next two months: The European Commission is expected to issue its final decision on marketing authorization.
Health Landscape
The recommendation follows the European Medicines Agency's scientific opinion pathway, which precedes binding European Commission authorization for new uses of medicines. It extends RSV prevention beyond the first season, where earlier preventive options had focused on the youngest infants.
If approved, the treatment would give parents of eligible children up to 24 months a preventive option for RSV during the second season of vulnerability. Availability and cost will depend on the final authorization and national healthcare arrangements in each country.
The takeaway
Preventive RSV options are extending to older infants at ongoing risk, so families of young children should ask their pediatricians whether eligibility applies once authorization is granted.
What happens next
The European Commission is expected to issue its final decision on marketing authorization within the next two months.
Further reading
Explore more in Children’s Health for context on pediatric respiratory illness and prevention.
Live Poll
Do you trust new preventive medicines for young children once regulators approve them?



